Group 1 - Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a price target of $20 [1] - The company is focusing on its oncology asset TPI-287, which is a blood-brain barrier crossing taxane in development for recurrent glioblastoma [1] - CNS Pharma's roadmap for TPI-287, along with a potential path forward with Berubicin and cash runway extending into the second half of 2026, positions the stock for recovery [1]